SONA NanoTech Ltd.

Published purpose

Sona is deploying its proprietary nanotechnology in the development of a rapid point-of-care (POC) test to screen for the current Coronavirus, COVID-19. The test will provide users with a quick-response lateral-flow test (LFT) to screen patients for the CoVID-19 virus. The test is expected to produce results in 5-15 minutes and is anticipated to be priced similarly to other LFT used to diagnose infectious diseases. There are currently no FDA approved lateral flow tests specific to CoVID-19. Due the significant need for a quick-response test, regulators such as the FDA are approving these assays through the emergency use authorization pathway. EUA is a path Sona will use in the future to make its test available in the US.